Williamson “Bill” Bradford, M.D., Ph.D.
Dr. Bill Bradford is an advisor and consultant in the biopharmaceutical industry. He has more than 20 years of experience in public and private companies, including executive, product development, medical affairs, and board roles.
Bill co-founded Indalo Therapeutics in 2016, a clinical-stage fibrosis company, was on the Board of Directors, and served as Chief Medical Officer until 2020. Previously he was Senior Vice President, Clinical Development at InterMune, where he successfully developed Esbriet® for Idiopathic Pulmonary Fibrosis and advanced a portfolio of therapeutics in the clinic, including treatments for hepatitis C virus. Bill has also held product development positions at IntraBiotics and Genentech and was an infectious disease specialist and researcher at the University of California San Francisco (UCSF). Bill currently serves on the Board of Directors of Hennepin Life Sciences, the Bluefield Project, and the scientific advisory boards for multiple companies.
Bill graduated cum laude with his B.A. from Williams College, received his M.D. from the University of North Carolina School of Medicine and Ph.D. in epidemiology from UC Berkeley, and completed his internal medicine residency and infectious disease fellowship at UCSF.